Impact of baseline SARS-CoV-2 antibody status on syndromic surveillance and the risk of subsequent COVID-19—a prospective multicenter cohort study

Autor: Marco Seneghini, Lorenz Risch, Philipp Kohler, Markus Ruetti, Ulrike Besold, Matthias Schlegel, Danielle Vuichard-Gysin, Stefan P. Kuster, Benedikt Wiggli, Angela Brucher, Sabine Güsewell, Eva Lemmenmeier, Reto Stocker, Christian R Kahlert, Allison McGeer, J. Carsten Möller, Andrée Friedl, Philip Alexander Rieder, Pietro Vernazza, Thomas Egger, Onicio Leal
Rok vydání: 2021
Předmět:
Zdroj: BMC Medicine, Vol 19, Iss 1, Pp 1-10 (2021)
Kohler, Philipp; Güsewell, Sabine; Seneghini, Marco; Egger, Thomas; Leal, Onicio; Brucher, Angela; Lemmenmeier, Eva; Möller, J Carsten; Rieder, Philip; Ruetti, Markus; Stocker, Reto; Vuichard-Gysin, Danielle; Wiggli, Benedikt; Besold, Ulrike; Kuster, Stefan P; McGeer, Allison; Risch, Lorenz; Friedl, Andrée; Schlegel, Matthias; Vernazza, Pietro; ... (2021). Impact of baseline SARS-CoV-2 antibody status on syndromic surveillance and the risk of subsequent COVID-19-a prospective multicenter cohort study. BMC medicine, 19(1), p. 270. BioMed Central 10.1186/s12916-021-02144-9
BMC Medicine
ISSN: 1741-7015
DOI: 10.1186/s12916-021-02144-9
Popis: Background In a prospective healthcare worker (HCW) cohort, we assessed the risk of SARS-CoV-2 infection according to baseline serostatus. Methods Baseline serologies were performed among HCW from 23 Swiss healthcare institutions between June and September 2020, before the second COVID-19 wave. Participants answered weekly electronic questionnaires covering information about nasopharyngeal swabs (PCR/rapid antigen tests) and symptoms compatible with coronavirus disease 2019 (COVID-19). Screening of symptomatic staff by nasopharyngeal swabs was routinely performed in participating facilities. We compared numbers of positive nasopharyngeal tests and occurrence of COVID-19 symptoms between HCW with and without anti-nucleocapsid antibodies. Results A total of 4812 HCW participated, wherein 144 (3%) were seropositive at baseline. We analyzed 107,807 questionnaires with a median follow-up of 7.9 months. Median number of answered questionnaires was similar (24 vs. 23 per person, P = 0.83) between those with and without positive baseline serology. Among 2712 HCW with ≥ 1 SARS-CoV-2 test during follow-up, 3/67 (4.5%) seropositive individuals reported a positive result (one of whom asymptomatic), compared to 547/2645 (20.7%) seronegative participants, 12 of whom asymptomatic (risk ratio [RR] 0.22; 95% confidence interval [CI] 0.07 to 0.66). Seropositive HCWs less frequently reported impaired olfaction/taste (6/144, 4.2% vs. 588/4674, 12.6%, RR 0.33, 95% CI 0.15–0.73), chills (19/144, 13.2% vs. 1040/4674, 22.3%, RR 0.59, 95% CI 0.39–0.90), and limb/muscle pain (28/144, 19.4% vs. 1335/4674, 28.6%, RR 0.68 95% CI 0.49–0.95). Impaired olfaction/taste and limb/muscle pain also discriminated best between positive and negative SARS-CoV-2 results. Conclusions Having SARS-CoV-2 anti-nucleocapsid antibodies provides almost 80% protection against SARS-CoV-2 re-infection for a period of at least 8 months.
Databáze: OpenAIRE
Externí odkaz: